מחיר רכישת החברה: CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) stands at the forefront of the bio-revolution, correcting genetic defects using "molecular scissors" to eradicate hereditary pathologies. This daily price action reflects an Enterprise Value market trend of 3390.95. Business growth is driven by the launch of Casgevy therapy, advancements in CAR-T, and a substantial liquidity reserve. The stability of R&D processes is guaranteed by a staff of top biochemists and international law experts.
CRISPR Therapeutics AG (CRSP) - פילוחי מדדים ודוחות פיננסיים

Enterprise value combines market capitalization with net debt, reflecting the actual price of a full business acquisition inclusive of liquid assets. For gene-editing pioneer CRISPR Therapeutics AG (CRSP), this metric demonstrates how its status as an innovation leader and the success of its first commercial therapies influence the overall valuation, which is clearly supported by the historical enterprise value trend.